Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03302234
Title	Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-small Cell Lung Cancer (MK-3475-598/KEYNOTE-598)
Recruitment	Completed
Gender	both
Phase	Phase III
Variant Requirements	Yes
Sponsors	Merck Sharp & Dohme Corp.
Indications	lung non-small cell carcinoma
Therapies	Pembrolizumab Ipilimumab + Pembrolizumab
Age Groups:	adult \| senior
Covered Countries	USA \| TUR \| POL \| LVA \| ITA \| IRL \| HUN \| GBR \| FRA \| ESP \| DEU \| CAN \| BRA \| AUS \| ARG